Oculentis Recalls Lentis IOLs in Philippines Due to Reports of Postoperative Opacification

November 10, 2017: By Joan McKenna

1 Ophthalmic NewsBerlin-based Oculentis has issued a voluntary recall in the Philippines for all Lentis intraocular lenses distributed and imported by Ophthaswissmed Philippines, Inc., with an expiration date of January 2017 to May 2020. The Philippines Food and Drug Administration (FDA) issued an advisory Oct. 27.

The agency said Oculentis has received notifications of sporadic late postoperative opacification of the lenses, which may compromise the transparency of the lens over time, potentially leading to reduced visual acuity.

The Philippines FDA said studies by Oculentis indicate that the opacification may be caused by phosphate remnants from a cleaning agent used in production.

The recall covers the Lentis (MDR-04652), Lentis Comfort (MDR-04654), Lentis T Plus (MDR-04647), Lentis T Plus X (MDR-04707), Lentis Comfort Toric (MDR-04708), Lentis M Plus (MDR-04651), Lentis M Plus X (MDR-04653), Lentis M Plus Toric (MDR-04719), and the Lentis M Plus X Toric (MDR-04706).

Oculentis says Lentis IOLs with an expiration of June 2020 or later are unaffected.

The recall notice did not specify whether lenses in other countries are affected or other regulatory bodies have been notified. Oculentis did not respond to a request for additional information.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Boy, 13, is First Patient Treated Commercially with Luxturna

Wet AMD Patients Regain Vision with Patch of Stem Cell-Derived RPE Cells, Moorfields Reports

ASCRS Meeting Returns to April Date in 2018, Avoiding Scheduling Conflicts

US FDA Approves Lucentis Prefilled Syringe for Diabetic Retinopathy, Diabetic Macular Edema

FDA Accepts pSivida’s Filing for Durasert as Treatment for Posterior Segment Uveitis

Eylea Meets Primary Endpoint in Phase III Trial for Nonproliferative Diabetic Retinopathy

Bascom Palmer Receives $12 Million Gift to Establish Research Center

SemaThera Announces $2 Million Financing, Licensing Deal for DME Candidate in China, Japan

Bausch + Lomb Inks Deal with Express Scripts Expanding Vyzulta Coverage

Melgen Seeks Bond, Appeals Conviction on Charges of Medicare Fraud

Avedro, FDA Agree on Design, Size of First Pivotal Phase III Trial for Epi-on Cross-linking

Iridex Reports 2017 Revenues of $41.6 Million

Bar-Ilan University Announces Nano-Drop Candidate to Correct Refractive Error

Essex Bio-Technology Agrees to Invest $5 Million in MeiraGTx, Developer of Gene Therapies

Clearside Biomedical Announces $85 Million Public Offering

ViewPoint Raises $35 Million for Topical Treatment Candidate for Cataracts, Presbyopia

Okogen Raises $10 Million in Series A Round for Viral Conjunctivitis Candidate

SightLife Surgical Acquires KAMRA Corneal Inlay from AcuFocus

Major Leaguer Tommy Pham Plays Through Keratoconus

Glaukos Reports 2017 Net Sales of $159.3 Million

Coming soon

2018 China Ophthalmic Market Report: An Analysis for 2017 to 2023